Our studies were not designed to directly test the role of CD4TREG in the tumor response to RT+CTLA4i, and despite the lack of effectiveness of antibodies targeting receptors highly expressed by intratumoral CD4TREG such as GITR and OX40, we cannot rule out a contribution of these cells to the therapeutic resistance to RT+CTLA4i. The gene discussed is TNFRSF4; the disease is neoplasm.